DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Top Q1 results today, August 11: MRF, Siemens, Zydus Lifesciences, RVNL, NBCC, Manappuram Finance among companies to announce earnings

Business Upturn 4 hrs ago·11 Aug 2026, 2:37 am

Zydus Lifesciences

Zydus Lifesciences is set to release its financial results for the first quarter of the current fiscal year. The company, a major player in the pharmaceutical sector, will disclose its earnings, which include details on revenue, profit, and operational performance for the period ending June 30.

Investors are closely watching this announcement to gauge the company's growth trajectory and its ability to maintain profitability amid a competitive market. Positive results could signal strong demand for its products, while any misses might raise concerns about future earnings potential.

Traders should focus on the company's guidance for the upcoming quarters and its strategy to navigate market challenges. Keeping an eye on the broader pharma sector trends will also help in understanding the context of these results.